Top entities: Regeneron Pharmaceuticals, False Claims Act of 1863, Levi & Korsinsky, Joseph E. Levi.

What category does this event fall under?

Regulatory — classified as class action lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Regulatory class action lawsuit

Regeneron Pharmaceuticals Faces Securities Lawsuit

Q: When did this event occur?

First reported Feb 07, 2025; last updated Feb 14, 2025.

Q: What is the market impact?

General. The class action lawsuit against Regeneron Pharmaceuticals could lead to a significant decline in its stock price due to potential financial penalties and damage to its reputation.

Q: What were the key actions taken?

Regeneron Pharmaceuticals made false statements · Levi & Korsinsky notified investors of lawsuit Regeneron Pharmaceuticals · Regeneron Pharmaceuticals violated False Claims Act of 1863

Analysis based on 11 articles · First reported Feb 07, 2025 · Last updated Feb 14, 2025

Sentiment

-50

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit against Regeneron Pharmaceuticals could lead to a significant decline in its stock price due to potential financial penalties and damage to its reputation. Investors in Regeneron Pharmaceuticals may suffer losses, and the pharmaceutical industry might face increased scrutiny regarding pricing and reporting practices.

Pharmaceuticals Biotechnology

Event Summary

Regeneron Pharmaceuticals is facing a class action securities lawsuit filed by Levi & Korsinsky on behalf of investors who suffered losses between November 2, 2023, and October 30, 2024. The lawsuit alleges that Regeneron Pharmaceuticals made false statements and concealed information by paying credit card fees to distributors for its product Eylea, which subsidized customer prices and provided a competitive advantage. These payments were allegedly not reported as price concessions, leading to an overstatement of the Average Sales Price (ASP) to federal agencies, thereby violating the False Claims Act of 1863. Investors have until March 10, 2025, to request to be appointed as lead plaintiff.

Key Actions

95 Regeneron Pharmaceuticals made false statements

90 Levi & Korsinsky notified investors of lawsuit Regeneron Pharmaceuticals

85 Regeneron Pharmaceuticals violated False Claims Act of 1863

Entities Involved

stock

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is facing a class action securities lawsuit for allegedly making false statements and concealing information regarding its product Eylea, which could lead to financial losses and reputational damage.

Importance 100.0 Sentiment -60.0

oth

False Claims Act of 1863

Regeneron Pharmaceuticals is accused of violating the False Claims Act of 1863 by overstating the Average Sales Price (ASP) reported to federal agencies for its product Eylea.

Importance 40.0 Sentiment 0.0

priv

Levi & Korsinsky

Importance 0.0 Sentiment 0.0

per

Joseph E. Levi

Importance 0.0 Sentiment 0.0

Relationships

Levi & Korsinsky related ↔ Joseph E. Levi

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard